TurnerTrends Stock Rating Report for ABPI
Data valid for week beginning August 25, 2008
|
ABPI [News]
|
Accentia Biopharmaceuticals Inc
|
Company Profile
"Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis- BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma- and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development- and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion- SinuTest, a test used in connection with the diagnosis of chronic sinusitis- and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis- and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Fri, 15 Aug 2008 23:25:04 Etc/GMT | Accentia Biopharmaceuticals sees Q3 loss narrow, receives Nasdaq notice (at bizjournals.com) | | Fri, 15 Aug 2008 15:25:09 Etc/GMT | Accentia Biopharmaceuticals cuts loss as research costs drop (at bizjournals.com) | | Thu, 14 Aug 2008 21:40:00 Etc/GMT | Accentia Reports Fiscal Third Quarter Financial Results (Business Wire) | | Thu, 14 Aug 2008 21:06:35 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (EDGAR Online) | | Thu, 14 Aug 2008 11:07:11 Etc/GMT | Q3 2008 ACCENTIA BIOPHARMACEUTICALS Earnings Release - Time Not Supplied (CCBN) | | Tue, 5 Aug 2008 14:55:10 Etc/GMT | Biovest joins cancer research collaborative (at bizjournals.com) | | Tue, 5 Aug 2008 13:20:00 Etc/GMT | Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System (Business Wire) | | Mon, 4 Aug 2008 10:02:05 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under (EDGAR Online) | | Fri, 25 Jul 2008 16:26:32 Etc/GMT | Biotech-Stock Mailbag: Genentech (at TheStreet.com) | | Mon, 21 Jul 2008 12:15:00 Etc/GMT | Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results (Business Wire) | | Thu, 17 Jul 2008 15:17:00 Etc/GMT | Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial (Business Wire) | | Mon, 14 Jul 2008 21:01:38 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statemen (EDGAR Online) | | Mon, 23 Jun 2008 20:03:00 Etc/GMT | Accentia Biopharmaceuticals to Present at the Jefferies Second Annual Healthcare Conference (Business Wire) | | Fri, 20 Jun 2008 21:26:15 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct (EDGAR Online) | | Fri, 20 Jun 2008 18:00:00 Etc/GMT | Biovest Misleading in BioVaxID Data (at Minyanville.com) | | Wed, 18 Jun 2008 20:09:30 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct (EDGAR Online) | | Tue, 17 Jun 2008 20:55:06 Etc/GMT | Accentia Biopharmaceuticals gets backing for key products (at bizjournals.com) | | Tue, 17 Jun 2008 17:30:00 Etc/GMT | Accentia Reports on Multiple Sclerosis Study: Revimmune(R) Shows Unprecedented Results in Reducing Disability and Improving Functions (Business Wire) | | Tue, 17 Jun 2008 14:37:00 Etc/GMT | Accentia Biopharmaceuticals Announces $8.5 Million Financing to Advance Key Strategies for SinuNase(TM) and Revimmune(TM) (Business Wire) | | Wed, 11 Jun 2008 14:11:14 Etc/GMT | ACCENTIA BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (EDGAR Online) | News provided by Yahoo! Finance |
|
